At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 120 enrolled
Drug / intervention
Etanercept +1 moredrug
Likely dose
Etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy
In Brief
A Phase 4 clinical trial evaluating Etanercept and Placebo for Psoriasis. Completed, enrolled 120 participants.
Detailed Summary
The purpose of this study is to evaluate the use of etanercept as a replacement therapy for ciclosporin in patients with plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedDec 2007
Primary CompletionNov 2009
TodayJul 2026
First PostedDec 27, 2007
Enrollment StartOct 1, 2007
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.5 years ago
Interventions
Etanerceptdrug
Etanercept 50 mg QW initiated during taper of ciclosporin
Placeboother
Randomized to placebo during taper of ciclosporin